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ABSTRACT  
Background: Proteus is a common uropathogen causing urinary tract infections in catheterised patients and those with urinary tract 
abnormalities. It may also lead to pyelonephritis, renal stones & bacteraemia. Multidrug resistant Proteeae isolates are major problem in 
treating nosocomial infections. Beta lactamase production is being increasingly demonstrated in most of the Proteus species. Apart from 
ESBL, Carbapenemase production is also emerging, thereby limiting the treatment options. Aim:  To isolate, speciate and study the 
antibiotic resistance pattern of the Proteeae isolates. To identify the extended spectrum beta lactamase and carbapenemase producing 
strains of Proteeae isolates by employing phenotypic methods. Materials and Methods: A total of 145 isolates of Proteus species isolated 
from different clinical samples- urine, pus and sputum, were included in this study. Antibiotic sensitivity testing was performed by Kirby-
Bauer disk diffusion method. Screening tests for ESBL & Carbapenemase production was confirmed by Disk diffusion method and 
Modified Hodge test respectively. Results: Out of the 145 Proteeae isolates, from various clinical samples 70 were from wound swabs, 
62 from urine, and 13 from respiratory specimens. The species were identified as 64 P.mirabilis, 48 P.vulgaris, 19 M.morganii, 5 
Prov.stuartii and 9 Prov.rettgeri. Different antibiotic resistance patterns were observed in different species. Providencia species showed 
resistance to most of the antibiotics than the Proteus species and M morganii. Of the total, 52 (36%) were ESBL producers. Among the 
ESBL producers 6 (11.5%) were Carbapenamase producers. Conclusion: The increasing incidence of multi drug resistant strains in Tribe 
Proteeae has made antimicrobial susceptibility testing more important. Avoidance of indiscriminate use of antibiotics is the first step in 
prevention of newly emerging drug resistant strains. 
KEYWORDS: Proteeae,  ESBL, Carbapenemase, Double disk Synergy test, Modified Hodge test. 
INTRODUCTION 
The Tribe Proteeae consists of Gram negative bacilli belonging 
to the family Enterobacteriaceae and it has three genera: 
Proteus, Morganella and Providencia. They are usually found 
in the environment causing hospital acquired and community 
acquired infections. Stamm in his study said that Proteus species 
is the third most common pathogen causing nosocomial 
infection (12%)[1]. They are mostly associated with urinary tract 
infections following catheterization especially in the patients 
who have structural or functional abnormalities. 90 % of Proteus 
infections are due to Proteus mirabilis. This is the most common 
species causing pyelonephritis, urolithiasis (bladder and kidney 
stone) leading to complications [2]. In the individuals with the 
long term indwelling catheters, Proteus mirabilis is the second 
leading cause of Catheter associated urinary tract infection 
(15%). This was studied by Jacobsen et a[3].  
Due to the emerging drug resistance, treatment of Proteeae 
infections is difficult. Multidrug resistant Proteeae isolates are 
major problem in treating nosocomial infections. Luzzaro et al., 
2009; D'Andrea et al., 2011 have reported the spread of the 
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multidrug resistant P.mirabilis in Europe[4,5]. Extended spectrum 
Beta lactamase (ESBL) production is being increasingly 
demonstrated in most of the Proteeae species. This is manifested 
as resistance to third generation cephalosporins (ceftazidime, 
cefotaxime and ceftriaxone) and monobactams but not 
cephamycins and carbapenems. According to the Bush Jacoby 
and Medeiros functional classification, ESBL is placed under 
the group 2be, and under class A, of Ambler's molecular 
classification [6]. ESBL producing organisms lead to treatment 
failure and spread of the resistance among the different strains. 
Therefore, screening for ESBL is necessary in order to provide 
effective treatment. 
Apart from ESBLs, carbapenemase production is also emerging 
among the multidrug resistant organisms. Carbapenem 
resistance is due to the altered penicillin binding proteins or 
outer membrane proteins. These are also Beta lactamases which 
hydrolyses not only the carbapenem antibiotics but also the 
penicillins, cephalosporins, and the monobactams. Hence 
detection of the carbapenemase production is also mandatory 
before prescribing antimicrobials. As per Ambler’s 
classification, they are classified as class A, B and D[6]. 
Earlier, ESBL production and Carbapenemase were rarely 
observed in Proteeae isolates but now the frequency of ESBL 
detection among the Proteus and Providencia species has 
increased. Therefore, this study demonstrates the susceptibility 
pattern of different species of Tribe Proteeae to commonly 
prescribed antibiotics and the prevalence of ESBL and 
Carbapenemase enzyme in the Proteeae isolates by phenotypic 
confirmatory methods.  
MATERIALS AND METHODS 
A total of 145 isolates of Proteus species from different clinical 
samples like urine, pus, sputum, endotracheal aspirates, 
collected from patients suffering from infections,  over a period 
of 1 year from January 2013 to January 2014 were included in 
this study. The study was carried out in the Department of 
Microbiology, Chettinad Hospital and Research Institute, 
Kelambakkam, Chennai. Consent was obtained from the 
patients. The Institutional Ethical Committee approval was 
obtained prior to commencing the study.                                                                                                                               
Species level identification of the members of the genus 
Proteus, Morganella and Providencia was made based on the 
property of swarming and biochemical tests like Catalase, 
Oxidase, Indole, Methyl red, Voges Proskauer, Citrate, Urease, 
Triple sugar iron agar, H2S production, Phenylpyruvic acid test, 
ornithine decarboxylation, and sugar fermentation test. 
Antibiotic susceptibility testing for all the three genera was 
determined  by Kirby-Bauer Disk Diffusion method, and 
diameter of the zone of inhibition was measured and interpreted 
according to the CLSI guidelines(7).  The isolates that were 
resistant to third generation cephalosporins in were tested for the 
production of Extended Spectrum Beta Lactamase by double 
disc synergy test.          
Detection of ESBL production:                                                               
The double disk synergy test was performed by drawing a lawn 
culture of the test strain with 0.5 McFarland standard on the 
Muller Hinton agar plate. Then a third generation cephalosporin 
disk and a combination disk containing cephalosporin plus 
clavulanate were placed at a distance of 15mm from each other 
(center to center) on the surface of the media with sterile forceps. 
The disks used were Ceftazidime- 30μg, Ceftazidime- 
Clavulanic acid- 30μg/10µg and Cefotaxime-30 μg, 
Piperacillin-tazobactam (100μg/10μg). Then the plates were 
incubated at 37 oC for 16-18hrs and the diameter of zones of 
inhibition around the disks was measured. A ≥ 5mm diameter 
increase in a zone diameter for either antimicrobial agent tested 
in combination with clavulanic acid with the zone diameter of 
the agent when tested alone confirms ESBL production by the 
strain. Detection of Carbapenemase production.                                                          
All the ESBL isolates that showed resistance to carbapenems 
(Imipenem and Meropenem) by disk diffusion and MIC 
determination method were confirmed for carbapenemase 
production by using the Modified Hodge Test, the phenotypic 
test for carbapenemase  production. A lawn culture of 
carbapenem susceptible strain (E.coli ATCC 25922) 
standardised with 0.5 McFarland was swabbed on the Muller 
Hinton agar plate. A Ertapenem 10 μg disc was placed in the 
middle of the plate. Suspected carbapenemase producing 
isolates were streaked from the edge of disk to edge of the plate. 
Four isolates were tested per plate. The plate was then incubated
at 370 C for 16-18 hrs. Clover leaf shaped indentation at the 
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intersection of the isolate and the E.coli within the zone of 
inhibition around the carbapenem disk is considered as positive 
for carbapenemase production.  
RESULTS 
Of the 145 Proteeae isolates 70 were from pus or wound swabs, 
62 from urine, and 13 from respiratory specimens.                                                                                                                  
Among the 70 exudate isolates, 39 (56%) were P.mirabilis, 18 
(26%) P.vulgaris, 4 (6%) Morganella, 4 (6%) Prov.stuartii and 
5 (7%) Prov.rettgeri. Among the 62 urine isolates, the most 
common was P.vulgaris 27 (43.5%), followed by 16 (26%) 
P.mirabilis, 14 (22.5%) Morganella, 1 (2%) Prov.stsuartii 4 
(6%) and Prov.rettgeri. Among the 13 respiratory isolates, 
mostly P.mirabilis and P.vulgaris were isolated - 9 (69%) and 3 
( 23%) respectively. Only one isolate of Morganella morganii 
was obtained. 
Figure 1.  Split up of clinical samples in Tribe Proteeae 
 
 
 
                                                                                                                                           Figure 3a. Speciation of Tribe Proteeae
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Figure 3b. Speciation of isolates from clinical samples 
 
Table No.1: Antibiotic sensitivity pattern of Tribe Proteeae  
 
EXUDATE (n=70) URINE (n=62) RESPIRATORY (n=13)
P.mirabilis 39 16 9
P.vulgaris 18 27 3
Morganella 4 14 1
Prov.stuartii 4 1 0
Prov.rettgeri 5 4 0
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Split up of isolates from clinical samples 
Antibiotic 
Percentage 
Sensitivity (%) 
P.mirabilis isolates  
(n=64) 
Percentage 
Sensitivity (%) 
of P.vulgaris 
isolates  
        (n=48) 
Percentage 
Sensitivity (%) of 
Morganella 
isolates  
(n=19) 
Percentage 
Sensitivity (%)  
of Prov.rettgeri 
isolates (n=9) 
 
Percentage 
Sensitivity (%)  
of Prov.stuartii 
isolates (n=5) 
Ampicillin 32 (50%) Intrinsic resistance Intrinsic resistance Intrinsic resistance Intrinsic resistance 
Cefazolin 30 (47%) Intrinsic resistance Intrinsic resistance Intrinsic resistance Intrinsic resistance 
Cefuroxime 33 (52%) Intrinsic resistance  Intrinsic resistance  Intrinsic resistance Intrinsic resistance 
Cefotaxime 37 (58%) 37 (77%) 16 (84%) 3 (33%) 0  
Cefipime 42 (66%) 40 (83%) 16 (84%) 4 (44%) 0 
Gentamicin 44 (69%) 37 (77%) 16 (84%) 3 (33%) 1 (20%) 
Amikacin 48 (75%) 37 (77%) 18 (95%) 3 (33%) 1 (20%) 
Ciprofloxacin 48 (75%) 29 (60%) 17 (89%) 4 (44%) 2 (40%) 
Cotrimoxazole 27 (42%) 22 (46%) 9 (47%) 4 (44%) 0   
Piperacillin-
Tazobactam 
54 (84%) 22 (46%) 18 (95%) 8 (89%) 1 (20%) 
Meropenem 48 (75%) 22 (46%) 17 (89%) 4 (44%)  1 (20%) 
Imipenem 63 (98%) 46 (96%) 19 (100%) 8 (89%) 3 (60%) 
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Figure 3b shows speciation of the Proteeae isolates from the 
clinical samples- exudate 70, urine 62 and respiratory 14.  
Among the 70 exudate isolates, 39 (56%) were P.mirabilis, 18 
(26%) P.vulgaris, 4 (6%) Morganella, 4(6%) Prov.stuartii and 
5 (7%) Prov.rettgeri. Among the 62 urine isolates, the most 
common was P.vulgaris 27 (43.5%), followed by 16 (26%) 
P.mirabilis, 14 (22.5%) Morganella, 1 (2%) Prov.stsuartii, 4 
(6%) Prov. rettgeri.  
Among the 13 respiratory isolates, Providencia species was not 
isolated. The number of P.mirabilis and P.vulgaris isolates were 
9 (69%) and 3 (23%) respectively. Only one isolate of 
Morganella morganii was obtained. 
 
Figure 4.  Percentage (%) of resistance of Tribe Proteeae isolates to different antibiotics
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ESBL producers: The isolates which were resistant to third 
generation cephalosporins were tested for the production of 
Extended Spectrum Beta Lactamase (ESBL) by double disk 
synergy test and the interpretation was recorded as mentioned 
previously. Among the 145 Tribe Proteeae isolates 52 (36%) 
were ESBL producers. 27 out of 64 P.mirabilis, 14 out of 48  
P.vulgaris, 2 out of 19 Morganella, 9 out of Providencia 
species.  
 
Figure 5. ESBL producer in Double disk synergy test 
 
Figure 6. ESBL among different species 
Carbapenemase producers among the ESBL strains: Among 
the 52 ESBL producers, only 6 (11.5%) were found to be 
resistant to carbapenems (imipenem and meropenem) by disk 
diffusion method. Carbapenemase production was confirmed by 
Modified Hodge test as mentioned previously. None of the 
Morganella isolates were found to be resistant. 1 P.mirabilis, 1 
Prov.rettgeri and 2 P.vulgaris and 2 Prov.stuartii.  
Table 2. Carbapenemase production in isolates from 
different samples 
 Urine Exudate 
P.mirabilis - 1 
P.vulgaris 2 - 
Prov.stuartii - 2 
Prov.rettgeri 1 - 
Figure 7. Modified Hodge test for Carbapenemase 
detection 
Clover leaf shaped indentation at the intersection of test 
organism and the E.coli with in the zone of inhibition around the 
carbapenem disk is considered as positive for carbapenemase 
production 
The isolates which produced ESBL also showed resistance to 
cotrimoxazole, probably the drug resistance emerging. Among 
the 52 ESBL isolates, all the ESBL produced Proteus, 
Morganella, Providencia species were resistant to 
cotrimoxazole.  
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Figure 8. Resistance pattern to carbapenems among the ESBL producing Proteeae isolates 
 
Figure 9. Number of ESBL producers resistant to cotrimoxazole
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Tribe Proteeae are widely distributed in the environment as 
saprophytes. Within this tribe, the most common human 
pathogens belong to the genus Proteus [11]. Members of this 
genus can also be called as nosocomial pathogens and can cause 
infections of the respiratory tract, and more commonly wound 
infections. Mostly they are associated with urinary tract 
infections following catheterisation especially in the patients 
who have structural or functional abnormalities. 90 % of Proteus 
infections are due to Proteus mirabilis.  Of the clinical samples 
collected, the maximum number of Proteeae isolates were from 
the exudate specimens (wound swabs, pus, abdominal abscess), 
accounting for 48% of all the specimens (Figure no. 1). Of the 
total of 145 isolates, 64 (45%) were found to be P.mirabilis, 
48(33%) were P.vulgaris, 19 (13%) were Morganella morganii, 
5 (3%) were Providencia stuartii , 9 (6%) were Providencia 
rettgeri (Figure no. 3a).  This study correlates with the study of 
Feglo et al where P.mirabilis was the commonest isolate- 
61%.[12]  But in a study of Reslinski 2005, Proteus species were 
commonly found in urine than other clinical specimens [13 ].  
The number of Proteus mirabilis isolates from both exudate and 
respiratory samples was 39 and 9 respectively. The other 
common species isolated was P.vulgaris which was more 
common in urine than exudate samples (Figure no.3b) in the 
results which correlates with the study of Pandey et al[18]. 
In this study P.mirabilis isolates were 97% sensitive to 
Imipenem followed by 84% to piperacillin-tazobactam, 75% to 
meropenem, 75% ciprofloxacin and amikacin, 66% to cefipime. 
Although P.mirabilis were sensitive to most of the antibiotics, 
low sensitivity were observed to cotrimoxazole 42% and 
ampicillin 50% (Table no.1). In 1979 Chow et al in his study, 
has reported a multiple resistant P.mirabilis strain which was 
resistant to ampicillin along with cotrimoxazole, cephalothin, 
and  aminoglycosides[14].                                                                                                                   
Most of the P.vulgaris isolates were sensitive to all antibiotics 
except ampicillin, cefazolin, and cefuroxime to which these 
organisms were intrinsically resistant. (Table no.1) Low 
sensitivity was noted only in cotrimoxazole 46%.  This study 
correlates with the study by England Wales 2003 where multiple 
resistance patterns was not observed [15]. 
Providencia species exhibited more resistance to antibiotics 
than the other genera. It was observed that Prov.stuartii and 
Prov.rettgeri showed only 60% and 89% sensitivity to 
imipenem respectively. Prov.stuartii showed 100% resistance to 
third generation cephalosporin and only 20% of the isolates 
were sensitive to aminoglycosides, cotrimoxazole and 
meropenem (Table no.1). Similar results were observed in a 
study by Vinoth et al, which showed that Providencia species 
were 90% resistant to third generation cephalosporins,70% 
amikacin[16].  
Most of the Morganella species were sensitive to all the 
antibiotics. The antibiotic resistance among the Proteeae 
species may be due to the indiscriminate use of antibiotics which 
provides selective pressure and thereby leading to development 
of resistant organisms (Levy 1999)[17 ].The Proteeae isolates that 
were resistant to third generation cephalosporins were tested for 
the production of ESBL by double disc synergy test. The picture 
shown in figure no.5 confirms ESBL production. According to 
figure no.6 of this study, out of total 145 Tribe Proteeae isolated, 
52 isolates (36%) were extended spectrum beta lactamase 
producers i.e 27 (42%) out of 64 P.mirabilis, 14(29%) out of 48 
P.vulgaris, 2 (11%) out of 19 Morganella  and 9(64%)  out of 
14 Providencia species. In a study of Jitendra Kumar Pandey 
2013, 48.8%  of the isolates were ESBL producers which were 
found to correlate with the results of this study [18]. Whereas in a 
study by Joanna et al, among the 50 P.mirabilis  strains isolated 
11 (22%) were ESBL producers which is slightly lower from 
this study[19]. ESBL production was found to be more common 
among the Providencia species than Proteus and Morganella 
whereas in a study by Feglo et al ESBL production among the 
Proteus species was more 77%. [12].                                       
                                                                              
Figure No.8 demonstrates the percentage of carbapenemase 
producers among the ESBL producing isolates. The picture 
shown in figure no.7 is positive for Modified Hodge Test. 
Among the 52 ESBL producers, 6(11.5%) were found to be 
resistant to carbapenems by disk diffusion method. These 6 
isolates were confirmed by Modified Hodge test for 
carbapenemase production, according to CLSI guidelines [8]. 
Among these 6 isolates Prov.stuartii and P.vulgari isolates were 
2 each, 1 was Prov.rettgeri, and 1 P.mirabilis.(Table no.2). A 
study in China showed that P. mirabilis from pleural drainage 
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fluid was resistant to carbapenems and showed the presence of 
the gene blaKPC
[20] .A study in Brazil by Ana Paul et al isolated a 
carbapenem resistant Providencia rettgeri in which bla NDM-1 
was detected[21]. Therefore various genes responsible for this 
carbapenem resistance among the Proteus species is also 
emerging like ESBL. Therefore the results of this study show 
that the most effective antibiotic against the Proteus species was 
Imipenem followed by ciprofloxacin and amikacin. Also it has 
been noted that all the 52 ESBL producing isolates showed 
resistance to cotrimoxazole (Figure no. 9). The high antibiotic 
resistance may lead to increase in infections and the spread of 
the resistance to other individuals. 
CONCLUSION 
This study enumerates the different species of Tribe Proteeae; 
the prevalence of ESBL producing Proteeae isolates was 
significant 36% and the prevalence of Carbapenemase 
production was found to be 11.5%. These resistant strains not 
only cause serious infections among the individuals but also act 
as potential reservoirs of drug resistance genes which can be 
transferred to other organisms. The high level of ESBL 
production and the carbapenemase production are the indication 
of the resistance which has been recorded in many studies. 
Therefore, routine detection of ESBL and Carbapenemase 
detection should be carried out in each laboratory by standard 
methods recommended by Clinical Laboratory standard 
Institute (CLSI).  This is important to control the spread of 
infections, to control the multi drug resistance, and to initiate 
proper therapeutic approach. And also indiscriminate use of the 
antibiotics should be avoided as the treatment options are 
limited in multidrug resistant strains.  
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